Glypican‐3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment
Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular
carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently …
carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently …
Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma
X Zheng, X Liu, Y Lei, G Wang, M Liu - Frontiers in oncology, 2022 - frontiersin.org
Glypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated
in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues …
in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues …
Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity
W Li, L Guo, P Rathi, E Marinova, X Gao… - Human gene …, 2017 - liebertpub.com
T cells engineered to express CD19-specific chimeric antigen receptors (CARs) have shown
breakthrough clinical successes in patients with B-cell lymphoid malignancies. However …
breakthrough clinical successes in patients with B-cell lymphoid malignancies. However …
Normal alpha-fetoprotein hepatocellular carcinoma: are they really normal?
CW Lee, HI Tsai, WC Lee, SW Huang, CY Lin… - Journal of clinical …, 2019 - mdpi.com
Introduction: serum alpha-fetoprotein (AFP) was routinely employed as a tumor marker for
screening, diagnosis, and treatment follow-up of hepatocellular carcinoma (HCC). However …
screening, diagnosis, and treatment follow-up of hepatocellular carcinoma (HCC). However …
Practical immunohistochemistry in neoplastic pathology of the gastrointestinal tract, liver, biliary tract, and pancreas
HL Wang, CJ Kim, J Koo, W Zhou… - … of pathology & …, 2017 - meridian.allenpress.com
Context.—Immunomarkers with diagnostic, therapeutic, or prognostic values have been
increasingly used to maximize the benefits of clinical management of patients with …
increasingly used to maximize the benefits of clinical management of patients with …
Imaging the expression of glypican-3 in hepatocellular carcinoma by PET
Z Wang, YJ Han, S Huang, M Wang, WL Zhou, HS Li… - Amino Acids, 2018 - Springer
Abstract The glypican-3 (GPC3) receptor is overexpressed in hepatocellular carcinoma
(HCC) and is a potential diagnostic and therapeutic target. GPC3-targeted molecular …
(HCC) and is a potential diagnostic and therapeutic target. GPC3-targeted molecular …
CRISPR‐induced exon skipping of β‐catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer
CRISPR/Cas9‐driven cancer modeling studies are based on the disruption of tumor
suppressor genes by small insertions or deletions (indels) that lead to frame‐shift mutations …
suppressor genes by small insertions or deletions (indels) that lead to frame‐shift mutations …
[HTML][HTML] Uncovering essential anesthetics-induced exosomal miRNAs related to hepatocellular carcinoma progression: a bioinformatic investigation
N Huang, J Fang, F Du, J Zhou, Y Li… - BMC Medical …, 2024 - ncbi.nlm.nih.gov
Background Anesthetic drugs may alter exosomal microRNA (miRNA) contents and mediate
cancer progression and tumor microenvironment remodeling. Our study aims to explore how …
cancer progression and tumor microenvironment remodeling. Our study aims to explore how …
Alternative biomarkers to predict tumor biology in hepatocellular carcinoma
P Abreu, R Ferreira, V Mineli, MA Ribeiro… - Anticancer …, 2020 - ar.iiarjournals.org
Hepatocellular carcinoma (HCC) is the most frequent primary malignant liver tumor, with
more than 800,000 new cases diagnosed each year and with high mortality, ranking fourth …
more than 800,000 new cases diagnosed each year and with high mortality, ranking fourth …
[HTML][HTML] Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know
SL Zhang, HL Wang - Human Pathology, 2023 - Elsevier
Ancillary tests are commonly used in the surgical pathology setting for diagnosing
challenging neoplastic diseases of the liver and biliary tract, while histology and clinical …
challenging neoplastic diseases of the liver and biliary tract, while histology and clinical …